TABLE 1.
Baseline clinical characteristics
| Baseline characteristics (n = 202) | Patients with sonographic healing (n = 79) | Patients without sonographic healing (n = 123) | |
|---|---|---|---|
| Median (IQR) or percentage (n) | p value | ||
| Age at diagnosis (years) | 21 IQR (17–32) | 25 IQR(19–37) | 0.27 |
| Gender (male) | 48 (38) | 51 (63) | 0.67 |
| Duration of disease (years) | 8 IQR (3–13) | 9 IQR (4–19) | 0.76 |
| Previous bowel resection | 29 (23) | 37 (46) | 0.23 |
| Current smoking | 20 (16) | 37 (45) | 0.014* |
| Disease phenotype | |||
| B1 (inflammatory) | 63.3 (50) | 29.3 (36) | <0.00* |
| B2 (stricturing) | 17.7 (14) | 52.0 (64) | <0.00* |
| B3 (penetrating) | 19.0 (15) | 18.7 (23) | 0.959 |
| Medication at time of IUS | |||
| Oral prednisolone/budesonide | 6 (7.6) | 12.2 (15) (2 missing) | 0.30 |
| 5‐aminosalicilic acid | 10.1 (8) | 14.7 (19) (2 missing) | 0.28 |
| 6‐mercaptopurine | 8.9 (7) | 6.5 (8) | 0.13 |
| Azathioprine | 35.4 (28) | 39 (48) | |
| Methotrexate | 5.6 (4) | 13 (16) | 0.07 |
| Anti‐tumor necrosis factor | |||
| Infliximab | 39.2 (31) | 25.2 (31) | 0.04* |
| High dose Infliximab | 5.1 (4) | 7.3 (9) | 0.52 |
| Adalimumab | 10.1 (8) | 22.0 (27) | 0.03 |
| High dose adalimumab | 2.2 (2) | 2.4 (3) | 0.97 |
| Ustekinumab | 6.7 (6) | 6.5 (8) | 0.77 |
| Vedolizumab | 0 | 4.1 (5) | 0.14 |
| High dose Vedolizumab | 1.3 (1) | 1.6 (2) | 0.84 |
| Other | 1.3 (1) | 0 | 0.21 |